Skip to content

ISLAA

International Symposium on Left Atrial Appendage

Agenda

Session I – LAA Exclusion Anatomy and Imaging

Session 1 – LAA Exclusion Anatomy and Imaging –

Chair 

Discussants 

7:50 AM – 8:00 AM                   Understanding the LAA Anatomy – Relevance to Systemic Thromboembolization and   Exclusion Techniques

8:00 AM – 8:10 AM                   Pre and Intra-procedural TEE Imaging for Effective LAA Exclusion 

8:10 AM – 8:20 AM                    CT Imaging for LAA Exclusion – Pre and Post-Procedural Assessment 

8:20 AM – 8:30 AM                   New Insights into Left Atrial Appendage Role in Atrial Arrhythmia's Origin and   Maintenance 

8:30 AM – 8:40 AM                   Is the Thromboembolic Risk of Rheumatic AF Different Than Non-Valvular AF and Why?                                                        What is the Role of LAA Closure?

8:40 AM – 8:50 AM                   Panel Discussion

Session II – Live Case 1

Chair                                          

Discussants 

8:50 AM – 9:30 AM                    Live Case

9:30 AM – 9:40 AM                    The John Madden Memorial Lecture - Humble Beginnings in Percutaneous LAA Closure

9:40 AM – 9:50 AM                    Post Implant Endothelialization - Mechanism and Predictors LAA Leaks Among Various      LAA Exclusion Devices 

9:50 AM – 10:00 AM                  Implications of Leaks on Systemic Thromboembolism and Long-Term OAC/APT After LAA  Occlusion 

10:00 AM – 10:10 AM                Management of Endocardial Occluder Leaks  - Plugs/Coils/RF Ablation

10:10 AM – 10:20 AM                Management of Epicardial Exclusion Device Leaks/Long Stumps

10:20 AM – 10:30 AM                Panel Discussion

10:30 AM – 10:45 AM                Break

Session III – Live Case 2

Chair                                         

Discussants 

10:45 AM – 10:55 AM                Safe and Effective Dry Epicardial Access - Micro Puncture, Epiep and More Practical Tips

10:55 AM – 11:30 PM                Live Case

11:30 AM – 11:40 AM                Best Practices Managing Post-Procedural Pericardial Drain and Pericarditis – Colchicine,    Steroids, Liposomal Bupivacaine and More 

11:40 AM – 11:50 AM                How to Manage Acute and Sub-acute Pericardial Effusions After LAA Closure Device          Placement? 

11:50 PM – 12:15 PM                Panel Discussion

12:15 PM – 1:00 PM                  Lunch Break

Session IV

Chair                                        

Discussants 

1:00 PM – 1:10 PM                    Customizing Transseptal Access & Sheath Type Based on Anatomy and Orientation of LAA 

1:10 PM – 1:50 PM                    Live Case

1:50 PM – 2:00 PM                    How Do You Manage Patients with Persistent LAA Filling Defect (Thrombus) - More            Anticoagulation or LAAO? 

2:00 PM – 2:10 PM                    Abridged POst LAAO OAC & DAP Prescription is As Good as the IFU Guidelines

2:10 PM – 2:20 PM                    ICE is a Better Tool for Intraprocedural Management of LAA Closure Devices 

2:20 PM – 2:30 PM                    Device Related Thrombus – Is the True Achilles Heel of LAAO - Incidence, Mechanism and  Prevention

2:30 PM – 2:40 PM                    How to Manage DRT in Patients OAC Tolerant and Intolerant 

2:40 PM – 2:50 PM                    How to Manage LAAO Device Embolization 

2:50 PM – 3:10 PM                    Panel Discussion

3:10 PM – 3:30 PM                    Break       

Session V

Chair                              

Discussants 

3:30 PM – 3:40 PM                    LAA Reservoir Function and Impact of Exclusion Versus Occlusion 

3:40 PM – 3:50 PM                    Impact of LAA Exclusion – ANP, RAAS, And LAA Homeostasis 

3:50 PM – 4:30 PM                    Live Case 

4:30 PM – 4:40 PM                    LAA Exclusion in Arrhythmia Rx – LAALA AF, Amaze and More 

4:40 PM – 5:00 PM                    Debate: Endocardial LAA Isolation with RFA Followed by an Occluder Placement is a          Better Strategy for Persistent AF Patients? Epicardial LAA Exclusion and RFA is a Better Strategy for Persistent AF Patients?

5:00 PM – 5:10 PM                    Economics of LAAO Program - The Organizational Perspective 

5:10 PM – 5:30 PM                    Panel Discussion

Session VII

Chair       

Discussants 

7:10 AM – 7:20 AM                   I am Not an Implanting Physician – Which Patient Do I Send for Consideration of LAA                                                          Closure 

7:20 AM – 7:30 AM                   How Do You Manage a Patient with GI Bleeding – A Gastroenterologist Perspective 

7:30 AM – 7:40 AM                   Thank Zeus for LAA Closure 

7:40 AM – 7:50 AM                   Sub-Clinical Atrial Fibrillation and Stroke Understanding the Connection 

7:50 AM – 8:00 AM                   How Can We Preemptively Identify High Risk Patients with ICH and Treat Them with                                                              LAAO?

8:00 AM – 8:10 AM                   Antiplatelet and Anticoagulants Time to Start Thinking About LAAO

8:10 AM – 8:30 AM                    Debate: Lariat Followed by RFA Versus Convergent Followed by RFA

8:30 AM - 8:50 AM                     Panel Discussion

8:50 AM – 9:10 AM                     Break

Session VIII

Chair                      

Discussants 

9:10 AM – 9:20 AM                    Updates on Newer LAA Occlusion Devices – An Overview and Relevance (Includes Aegis/Occlutech/Prolipsis/Cardia/Acoredis and More 

9:20 AM – 9:40 AM                    Debate: New Indications for LAA Closure: WATCHMAN/LAA Occluder Should be Done Along with AF Ablation in the Same Setting? 

9:40 AM – 9:50 AM                    Anatomic Considerations for AtriClip – Mini-Thoracotomy/Vats/Open Approach 

9:50 AM – 10:10 AM                    AtriClip Recorded Case 

10:10 AM – 10:20 AM                  Post-Procedural Management of AtriClip – Pericarditis/Anticoagulation/Imaging 

10200 AM – 10:40 AM                Lambre Recorded Case 

10:40 AM – 11:00 AM                WaveCrest Recorded Case 

11:00 AM – 11:20 AM                Panel Discussion

Session IV Miscellaneous LAA Occlusion Devices

Chair                              

Discussants

11:20 AM – 11:30 AM                Conforma LAA Occlusion Device 

11:30 AM – 11:40 AM                 WATCHMAN Trials Update

11:40 AM – 11:50 AM                 Amplatzer Cardiac Plug Trials Update – Amulet IDE & More 

11:50 AM – 12:00 AM                AtriClip, LAAOS III, Convergent and More – Treating AF and LAA at the same time 

12:00 PM – 12:20 PM                Panel Discussion      

12:20 PM – 1:00 PM                   Lunch

Session X

Chair                          

Discussants

1:00 PM – 1:10 PM                    What Other Data Does It Take for LAAO Indication Change from II A to I 

1:10 PM – 1:20 PM                    WATCHMAN vs WATCHMAN FLX – What is Different and Better?

1:20 PM – 1:30 PM                    Feasibility and Safety of Same Day LAAO and TAVR/TMVR WATCHMAN-TAVR Study and                                                      More 

1:30 PM – 1:40 PM                    Transitioning LAA Exclusion Technology from Clinical Trials to Market Place – Lessons                                                            From the Lariat, WATCHMAN and ACP Experience 

1:40 PM – 1:50 PM                    How to Build A Successful LAA Referral Program 

1:50 PM – 2:00 PM                    Managing AF Patient with PFO Closure/ASD Role of Ablation, LAAO and PFO Closure                                                            Devices

2:00 PM – 2:20 PM                    Panel Discussion

2:20 PM – 2:40 PM                     Break

Session XI Oral Anticoagulants in 2017

Chair                        

Discussants 

2:40 PM – 2:50 PM                    A Pathologist Perspective on The Future of Stroke Prophylaxis, LAA Occluders and Tissue                                                      Specific Targets 

2:50 PM – 3:00 PM                    NOACs Versus LAAO - PRAGUE 17, Catalyst, Champion and More

3:00 PM – 3:10 PM                    Understanding NOACs in the 21st Century – Dual/Triple Therapy and Balancing AF and                                                        CAD 

3:10 PM – 3:20 PM                    My Patient Has an LAA Occluder And Had an Embolic CVA With No Evidence of Device                                                        Related Thrombus or Carotid Disease – What Do I Do? 

3:20 PM – 3:30 PM                    Safety of External Cardioversion in Patients with LAA Exclusion – What Do We Know? 

3:30 PM – 3:40 PM                    Understanding LAA Closure Device Related Erosions, Pumonary Vein and Mitral Valve                                                          Impingement 

3:40 PM – 3:50 PM                    Should LAA Exclusion be Performed Routinely in Patients that are High Risk for AF During                                                    Open Heart Surgery? Lessons Learnt From the Past and Future Strategies

3:50 PM – 4:10 PM                    Panel Discussion

Session XII Clinical Case

Chair 

Discussants 

4:10 PM – 5:20 PM                 

5:20 PM                                   Adjourn/Remarks

ISLAA 2020

Date

February 7-8, 2020
(Friday to Saturday)

Venue

New York Marriott Marquis
1535 Broadway, New York, NY 10036

Register


Click here to Register Now!

Scroll To Top